share_log

藥明合聯：截至2024年1月31日止股份發行人的證券變動月報表

WUXI XDC: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2024

Hong Kong Stock Exchange ·  Feb 5 17:02
Summary by Futu AI
藥明合聯生物技術有限公司（WuXi XDC Cayman Inc.）於2024年2月5日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年1月31日的股份變動情況。報告顯示，公司的法定/註冊股本結存維持在10,000,000,000股，每股面值0.00005美元，總額500,000美元，本月無增減變動。此外，公司根據2021年及2023年首次公開發售前的股份期權計劃，詳列了各期權計劃的授出日期、行使價格及股份期權數目，但本月並無新股份因行使股份期權而發行。公司確認，所有證券發行均已獲董事會授權，並符合香港聯合交易所有限公司證券上市規則的要求。
藥明合聯生物技術有限公司（WuXi XDC Cayman Inc.）於2024年2月5日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年1月31日的股份變動情況。報告顯示，公司的法定/註冊股本結存維持在10,000,000,000股，每股面值0.00005美元，總額500,000美元，本月無增減變動。此外，公司根據2021年及2023年首次公開發售前的股份期權計劃，詳列了各期權計劃的授出日期、行使價格及股份期權數目，但本月並無新股份因行使股份期權而發行。公司確認，所有證券發行均已獲董事會授權，並符合香港聯合交易所有限公司證券上市規則的要求。
Pharmaceutical United Biotechnology Co., Ltd. (WuXi XDC Cayman Inc.) filed an updated Securities Change Month Report with Hong Kong Trading and Settlement Limited on February 5, 2024, reporting stock changes as of January 31, 2024. The report showed that the company's regulated/registered capital reserves remained at 10,000,000,000 shares with a face value of $0.00005 per share for a total of $500,000, with no increase or decrease this month. In addition, under the share option plans prior to the initial public offering in 2021 and 2023, the Company has detailed the grant dates, exercise prices and number of share options for each option plan, but no new shares were issued this month as a result of the exercise of share options. The Company confirms that all securities issuance has been authorised by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Pharmaceutical United Biotechnology Co., Ltd. (WuXi XDC Cayman Inc.) filed an updated Securities Change Month Report with Hong Kong Trading and Settlement Limited on February 5, 2024, reporting stock changes as of January 31, 2024. The report showed that the company's regulated/registered capital reserves remained at 10,000,000,000 shares with a face value of $0.00005 per share for a total of $500,000, with no increase or decrease this month. In addition, under the share option plans prior to the initial public offering in 2021 and 2023, the Company has detailed the grant dates, exercise prices and number of share options for each option plan, but no new shares were issued this month as a result of the exercise of share options. The Company confirms that all securities issuance has been authorised by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.